Allergy Therapeutics (AGY) will start PQ Grass US approval studies in Q315. The convenience of the ultra-short course vaccine and US physician preference for subcutaneous immunotherapy (SCIT) could lead PQ to gain a large share of the c $2bn allergy immunotherapy (AIT) market given that it could be the first licensed seasonal SCIT. The acquisition of Alerpharma reinforces AGY’s position in the c €72m Spanish AIT market and enlarges its manufacturing capability. Our DCF valuation in
07 Jul 2015
Preparing to unlock US value of Pollinex Quattro
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Preparing to unlock US value of Pollinex Quattro
Allergy Therapeutics plc (AGY:LON) | 2.8 0 0.0% | Mkt Cap: 135.8m
- Published:
07 Jul 2015 - Author:
- Pages:
Allergy Therapeutics (AGY) will start PQ Grass US approval studies in Q315. The convenience of the ultra-short course vaccine and US physician preference for subcutaneous immunotherapy (SCIT) could lead PQ to gain a large share of the c $2bn allergy immunotherapy (AIT) market given that it could be the first licensed seasonal SCIT. The acquisition of Alerpharma reinforces AGY’s position in the c €72m Spanish AIT market and enlarges its manufacturing capability. Our DCF valuation in